Cost regulators for the NHS in England and Wales have not approved funding for TiGenix and Takeda’s Alofisel - the first allogeneic stem cell therapy to be approved for use across the European Union – for use in Crohn’s patients.......
Because of this, cost-effectiveness estimates are “highly uncertain” and the committee was unable to conclude on the most plausible cost-effectiveness estimate, NICE said.
http://www.pharmatimes.com/news/europes_first_allogeneic_stem_cell_therapy_rejected_by_nice_1249435
https://medcitynews.com/2019/04/report-takeda-adopts-value-based-pricing-for-crohns-stem-cell-therapy-in-europe/
"Under the value-based pricing arrangement reported Monday, Takeda would reimburse part or all of the cost of the drug if patients using it do not see improvement. It is also considering similar models for other high-priced drugs."
MSB Trading - 2020, page-12908
-
- There are more pages in this discussion • 10,253 more messages in this thread...
This thread is closed.
You may not reply to this discussion at this time.
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.17 |
Change
-0.025(2.10%) |
Mkt cap ! $1.330B | |||
| Open | High | Low | Value | Volume |
| $1.18 | $1.22 | $1.15 | $6.344M | 5.404M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 8683 | $1.16 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.17 | 32999 | 1 |
View Market Depth
| Last trade - 16.10pm 15/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |